Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115088
Chunk: 171

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 171
---
 incentive to sell because it will still profit on sales due to the lower price at which they acquired their shares compared to the other securityholders. Other securityholders may not experience a similar rate of return on the securities they**

<div align='center'>102</div>

purchased due to differences in the purchase prices and the current trading price. For example, based on the closing price of our Common Stock of $5.43 on May 5, 2025, Oramed may experience a potential profit of up to $5.42 per Resale Share given that the exercise price of the Penny Warrants is $0.01 per share. Depending on the price, the public securityholders may have paid significantly more than the Selling Stockholder for any shares they may have purchased in the open market based on variable market prices and therefore may not be able to experience the same positive rates of return on securities they purchase.

<div align='center'>103</div>

### MARKET AND INDUSTRY DATA
Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled “Risk Factors.” These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

<div align='center'>104</div>

### USE OF PROCEEDS
We will receive no proceeds from the sale of the Resale Shares by the Selling Stockholder. The Selling Stockholder will pay any underwriting discounts, selling commissions or transfer taxes incurred in disposing of the Resale Shares and the expenses of any attorney or other advisor they decide to employ. We will bear all other costs, fees and expenses incurred in effecting the registration of the Resale Shares covered by this prospectus. These may include, without limitation, all registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with applicable securities laws